InvestorsHub Logo
Followers 9
Posts 257
Boards Moderated 0
Alias Born 06/12/2015

Re: None

Friday, 10/23/2015 10:18:28 AM

Friday, October 23, 2015 10:18:28 AM

Post# of 144814
Does anyone understand the difference between Macks treatment (just approved by FDA) vs Pharmacyte's??

Here is a snippet from Mack's announcement:

ONIVYDE™ (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Is the differnce Pharmacyte targets tumors that are not growing vs Macks targets tumors that are growing??

Apparently Macks treatment has serious side effects. To me this provides Pharmacyte with a distinct advantage....

Would be nice for Pharmacyte to differentiate in future announcements...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News